S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL

CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL

Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy

Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL

Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL